Display options
Cite
Poplawski P, Nauman A. Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130. Thyroid Res. 2008;1(1):5doi: 10.1186/1756-6614-1-5.
Poplawski, P., & Nauman, A. (2008). Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130. Thyroid research, 1(1), 5. https://doi.org/10.1186/1756-6614-1-5
Poplawski, Piotr, and Nauman, Alicja. "Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130." Thyroid research vol. 1,1 (2008): 5. doi: https://doi.org/10.1186/1756-6614-1-5
Poplawski P, Nauman A. Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130. Thyroid Res. 2008 Oct 13;1(1):5. doi: 10.1186/1756-6614-1-5. PMID: 19014670; PMCID: PMC2583984.
Copy Download .nbib Format: NLM
Share it on

Thyroid Res. 2008 Oct 13;1(1):5. doi: 10.1186/1756-6614-1-5.

Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130.

Thyroid research

Piotr Poplawski, Alicja Nauman

Affiliations

  1. Department of Biochemistry and Molecular Biology, The Medical Centre of Postgraduate Education, Warsaw, Poland. [email protected].

PMID: 19014670 PMCID: PMC2583984 DOI: 10.1186/1756-6614-1-5

Abstract

BACKGROUND: Triiodothyronine regulates proliferation acting as stimulator or inhibitor. E2F4 and E2F5 in complexes with pocket proteins p107 or p130 stop cells in G1, repressing transcription of genes important for cell cycle progression. p107 and p130 inhibits activity of cyclin/cdk2 complexes. Expression of all those proteins could be regulated by triiodothyronine. In clear cell renal cell carcinoma many disturbances in T3 signaling pathway was described, in that type of cancer also expression of some key G1 to S phase progression regulators was shown.

METHODS: We investigated role of T3 and its receptors in regulation of proliferation of HK2, Caki-2, Caki-1 cell lines (cell counting, cytometric analysis of DNA content) and expression of thyroid hormone receptors, E2F4, E2F5, p107 and p130 (western blot and semi-quantitative real time PCR). Statistical analysis was performed using one-way ANOVA.

RESULTS AND CONCLUSION: We show that T3 inhibits proliferation of HK2, and stimulates it in Caki lines. Those differences are result of disturbed expression of TR causing improper regulation of E2F4, E2F5, p107 and p130 in cancer cells.

References

  1. Clin Cancer Res. 2002 Dec;8(12):3850-6 - PubMed
  2. Toxicology. 2002 Dec 27;181-182:179-82 - PubMed
  3. Acta Biochim Pol. 2006;53(4):641-50 - PubMed
  4. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):193-208 - PubMed
  5. Acta Biochim Pol. 2007;54(3):595-602 - PubMed
  6. Cancer Res. 2000 Jul 15;60(14):3689-95 - PubMed
  7. Genes Chromosomes Cancer. 2000 May;28(1):126-30 - PubMed
  8. EMBO J. 1999 Apr 1;18(7):1878-90 - PubMed
  9. Oncogene. 2004 Nov 18;23(54):8756-65 - PubMed
  10. Rev Urol. 2007 Spring;9(2):47-56 - PubMed
  11. Mol Cell Endocrinol. 2003 Dec 31;213(1):1-11 - PubMed
  12. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2403-7 - PubMed
  13. Int J Cancer. 2002 Dec 20;102(6):601-7 - PubMed
  14. Cancer Biol Ther. 2006 Jan;5(1):84-8 - PubMed
  15. Genes Dev. 2001 Aug 15;15(16):2146-60 - PubMed
  16. Mol Biol Cell. 2004 Apr;15(4):1895-903 - PubMed
  17. Oncogene. 2006 Aug 28;25(38):5201-9 - PubMed
  18. Cancer Lett. 2000 Jul 31;155(2):145-52 - PubMed
  19. Steroids. 2008 Oct;73(9-10):1013-7 - PubMed
  20. Hepatology. 2003 Jan;37(1):79-86 - PubMed
  21. Oncogene. 2005 Apr 18;24(17):2796-809 - PubMed
  22. Scand J Urol Nephrol. 1994 Jun;28(2):135-40 - PubMed
  23. Carcinogenesis. 2002 Jan;23(1):25-33 - PubMed
  24. Eur J Cancer. 2002 Sep;38(14):1838-48 - PubMed
  25. Urology. 2006 May;67(5):873-80 - PubMed
  26. Mol Carcinog. 2002 May;34(1):25-34 - PubMed
  27. Mol Endocrinol. 2003 Jan;17(1):79-92 - PubMed
  28. Endocrinology. 1984 Jan;114(1):293-5 - PubMed
  29. Oncogene. 2008 Apr 24;27(19):2795-800 - PubMed
  30. J Hum Genet. 2004;49(6):312-318 - PubMed
  31. Thyroid. 2007 Nov;17(11):1039-48 - PubMed
  32. Cancer Res. 1997 Jun 15;57(12):2350-3 - PubMed
  33. Cancer Res. 1995 Apr 15;55(8):1649-54 - PubMed
  34. Breast Cancer Res Treat. 2001 Sep;69(2):115-22 - PubMed
  35. J Endocrinol Invest. 2001 Apr;24(4):253-61 - PubMed
  36. Cancer Res. 1996 Feb 1;56(3):623-32 - PubMed
  37. Cancer Res. 1997 Mar 1;57(5):795-8 - PubMed

Publication Types